Abstract:Joseph F Merola, 1, &ast Ahmad Z Amin 2, &ast 1 Brigham and Women's Hospital, Boston, Massachusetts, USA; 2 Northwestern University Feinberg, School of Medicine, Chicago, Illinois, USA &astThese authors contributed equally to this work Correspondence: Dr Joseph F Merola, Email Generalized pustular psoriasis (GPP) is the most severe form of pustular psoriasis and affects large areas of the body. GPP is a rare disease, and has a variable presentation; thus, its diagnosis is challenging. The onset of symptoms is rapid, with the appearance of painful skin erythema, followed by the widespread eruption of sterile pustules. Acute GPP (called a flare) is often accompanied by systemic symptoms, including high fever, pain in skin lesions, malaise, and fatigue. Approximately half of GPP flares require hospitalization, with an average inpatient duration of 10– 14 days. GPP prevalence estimates range from approximately 2– 124 cases per million persons, with a female predominance. The most common age of onset of GPP is 40– 60 years, although cases have been described in younger adults and children. GPP affects every aspect of patients' lives and has a high physical and psycho-social impact. Recent research on the interleukin-36 pathway associated with GPP led to the development of a GPP-specific treatment, spesolimab, which was approved by the US FDA in September 2022. This podcast explores the clinical presentation, disease course, and burden of disease in GPP, including differential diagnosis and common triggers of an acute flare. Keywords: generalized pustular psoriasis, interleukin-36 pathway, clinical presentation, disease burden, diagnosis Moderator: Dr Uwe Wollina Guests: Dr Joseph F Merola, Dr Ahmad Z Amin This Podcast was sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI). Dr. Uwe Wollina : Hello and welcome to the podcast series on generalized pustular psoriasis (GPP). This is episode one in a series of four podcasts on different aspects of GPP, and listeners can obtain further information on this condition in the subsequent episodes. My name is Uwe Wollina. I am former head of the department of Dermatology and Allergology at the Academic Teaching Hospital Dresden, Germany. I have the pleasure of moderating today's podcast where we will be talking about the clinical presentation, disease course, and burden of disease in GPP with our guest speakers, Dr. Joseph Merola and Dr. Ahmed Amin. Dr. Merola and then Dr. Amin, would you like to share some details regarding your clinical background? Thank you. Dr. Joseph F. Merola: Thanks for having me. I'm an Associate Professor at Harvard Medical School and the Director for the Center for Skin and Related Musculoskeletal Diseases at The Brigham and Women's Hospital here in Boston. Dr. Ahmad Z Amin: Hello and thanks for having me. I'm an Associate Professor of Dermatology at Northwestern University in Chicago, Illinois. I also serve as the Director of our psoriasis program. Dr. Uwe Wollina: Thanks for your introductions. It's a pleasure to join you today. Today we are going to discuss the clinical presentation and disease course of GPP, as well as discussing the potential triggers of an acute GPP flare. GPP can be debilitating for our patients, and we will discuss the different aspects of the burden of disease for patients with GPP. To start us off, could you provide an overview of generalized pustular psoriasis and tell us how common it is and who it affects? [00:01:52] Dr. Joseph F. Merola: So, generalized pustular psoriasis, which is often abbreviated as GPP, is one of several pustular psoriasis conditions that form a heterogeneous group of autoinflammatory diseases, typically characterized by sudden and painful skin inflammation, along with these small, sterile pustules. Widespread pustular psoriasis can affect large areas of the body, and we typically call that generalized pustular psoriasis. There are also localized variants that can affect palms and soles, known as palmoplantar pustulosis. Also, disease can be confined to the fingers, toes, and/or nail, typically for example, the nail bed, and is known as acrodermatitis continua of Hallopeau. GPP was first described in 1910 by a German dermatologist calle -Abstract Truncated-

Generalized Pustular Psoriasis, Acute Generalized Exanthematous Pustulosis, and Other Pustular Reactions: A Clinical Review

Generalized Pustular Psoriasis: A Review on Clinical Characteristics, Diagnosis, and Treatment

The Prevalence and Disease Characteristics of Generalized Pustular Psoriasis

Clinical Course and Characteristics of Generalized Pustular Psoriasis

Clinical Characteristics and Outcomes of Generalized Pustular Psoriasis Flares

Considerations for defining and diagnosing generalized pustular psoriasis

Diagnosis of Generalized Pustular Psoriasis

Pustular Psoriasis: From Pathophysiology to Treatment

Exploring the Clinical Presentation, Course, and Burden of Disease in Generalized Pustular Psoriasis [Podcast]

Exploring the Clinical Presentation, Course, and Burden of Disease in Generalized Pustular Psoriasis

Current Treatments for Generalized Pustular Psoriasis: A Narrative Summary of a Systematic Literature Search

Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease management

Clinical Disease Measures in Generalized Pustular Psoriasis

Generalized Pustular Psoriasis and Systemic Organ Dysfunctions

Treatment Options and Goals for Patients with Generalized Pustular Psoriasis

Characteristics and management of generalized pustular psoriasis (GPP): Experience from the Central and Eastern Europe (CEE) GPP Expert Network

Understanding the Pathogenesis of Generalized Pustular Psoriasis Based on Molecular Genetics and Immunopathology

Clinical and Disease Burden of Patients with Generalized Pustular Psoriasis: A Review of Real-World Evidence

Comprehensive Treatment Approaches in a Unique Case of Generalized Pustular Psoriasis

Pustular psoriasis and related pustular skin diseases

Evaluation of a Case Series of Patients With Generalized Pustular Psoriasis in the United States